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and Dave Singh1Abstract
Background: There is a need for novel anti-inflammatory therapies to treat COPD. The liver X receptor (LXR) is a
nuclear hormone receptor with anti-inflammatory properties.
Methods: We investigated LXR gene and protein expression levels in alveolar macrophages and whole lung tissue
from COPD patients and controls, the effect of LXR activation on the suppression of inflammatory mediators from
LPS stimulated COPD alveolar macrophages, and the effect of LXR activation on the induction of genes associated
with alternative macrophage polarisation.
Results: The levels of LXR mRNA were significantly increased in whole lung tissue extracts in COPD patients and
smokers compared to non-smokers. The expression of LXR protein was significantly increased in small airway
epithelium and alveolar epithelium in COPD patients compared to controls. No differences in LXR mRNA and
protein levels were observed in alveolar macrophages between patient groups. The LXR agonist GW3965
significantly induced the expression of the LXR dependent genes ABCA1 and ABCG1 in alveolar macrophage
cultures. In LPS stimulated alveolar macrophages, GW3965 suppressed the production of CXCL10 and CCL5, whilst
stimulating IL-10 production.
Conclusions: GW3965 did not significantly suppress the production of TNFα, IL-1β, or CXCL8. Our major finding is
that LXR activation has anti-inflammatory effects on CXC10, CCL5 and IL-10 production from alveolar macrophages.
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Cigarette smoking causes oxidative stress and inflamma-
tion in the airways [1], and is a major risk factor for the
development of chronic obstructive pulmonary disease
(COPD). This condition is characterised by progressive
airway inflammation [2] involving a complex network of
inflammatory cells. The number of lung macrophages is
increased in COPD [3], and these cells are thought to
play a key role in inflammation and tissue destruction in
COPD [4]. There is a need for novel anti-inflammatory
drugs to treat airway inflammation in COPD.
Liver X receptor (LXR) is a nuclear hormone receptor
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reproduction in any medium, provided the ora sensor of cellular cholesterol load [6], and regulates
the transcription of genes involved in cholesterol efflux
[7-9] and low density lipoprotein receptor degradation
[10]. Consequently, there has been much interest in the
potential of LXR agonists for the treatment of athero-
sclerosis [11], and it has been demonstrated that these
drugs reduce plaque size in animal models [12]. There
is also evidence that LXR activation results in anti-
inflammatory effects; LXR agonists reduce the expression
of inflammatory genes in animal models [13], suppress
the expression of a subset of LPS-induced inflammatory
genes in mouse macrophages [14] and inhibit cytokine
production from lymphocytes [15]. LXR exerts these anti-
inflammatory effects by preventing co-repressor removal
from the promoter regions of targeted genes, thereby sup-
pressing transcription [16,17].
Birrell et al. [18] demonstrated that the LXR agonist
GW3965 decreased LPS-induced airway neutrophilia inl Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Subject demographics for patients recruited
undergoing lung resection
NS S COPD
n 23 41 45
Gold stage I n/a n/a 9
Gold stage II n/a n/a 33
Gold stage III n/a n/a 3
Age (yrs) 64.5 (11.4) 63 (12.1) 64.2 (7)
Sex (M/F) 7/16 20/21 19/26
FEV1 (L) 2.3 (0.7) 2.4 (0.8) 1.7 (0.5)
FEV1 % predicted 102 (23.9) 92.4 (14.1) 68.3 (12.8)
FVC (L) 3 (0.8) 3.3 (0.9) 3.0 (0.9)
FEV1/FVC ratio (%) 73.3 (9) 73.4 (7.9) 58.9 (11.8)
Pack year history 0 41.7 (22.1) 51.5 (23)
Current smoker (%) 0 70 89
ICS users 0 0 12
Data shown are mean (sd). NS: non-smokers, S: smokers, FEV1: forced expiratory
volume in 1s, FVC: forced vital capacity, ICS: inhaled corticosteroid.
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in human alveolar macrophages, and GW3965 caused
up to 60% inhibition of cytokine production from these
cells. These findings suggest that LXR agonists may have
the potential to reduce airway inflammation in COPD
through the modulation of macrophage function. To fur-
ther investigate this possibility, the findings of Birrell
et al. need to be confirmed using COPD alveolar macro-
phages. COPD alveolar macrophages are phenotypically
different from healthy controls [19], and the effects of
LXR activation on cytokine production may therefore be
altered. Furthermore, it is not known whether LXR ex-
pression is changed within the lungs of COPD patients
compared to controls.
ATP-binding cassette (ABC) A1 is an LXR dependent
gene that is involved in cholesterol efflux [20]. ABCA1
appears to play a role in the polarisation of macrophages
away from the classical pro-inflammatory phenotype
(M1), towards the alternative phenotype (M2) that can
exert anti-inflammatory and tissue repair effects [21]. It
is possible that LXR mediated skewing of lung macro-
phages towards an alternative activation phenotype may
be therapeutically beneficial in COPD.
In order to further understand the potential of LXR
agonists as anti-inflammatory drugs in COPD, we have
investigated the expression and function of LXR in COPD
pulmonary cells, focusing on alveolar macrophages. We
studied the effects of LXR activation on cytokine pro-
duction from COPD compared to control alveolar mac-
rophages and evaluated possible effects on alternative
macrophage activation. We investigated whether LXR ex-
pression was changed in COPD compared to control lungs;
we observed, as expected, LXR expression in alveolar mac-
rophages, but also demonstrated expression in airway
epithelium and in lymphocytes. We therefore also stud-
ied the effects of LXR activation on cytokine production




109 patients undergoing surgical resection for lung can-
cer were recruited (demographics shown in Table 1). 10
COPD patients and 10 healthy non-smokers were also
recruited to donate peripheral blood (demographics shown
in Additional file 1). COPD patients had ≥ 10 pack years
smoking history, typical symptoms and airflow obstruction.
Controls were either smokers (S) with normal lung func-
tion or lifelong non-smokers (NS). Immunohistochemistry
and gene expression experiments used historically col-
lected samples allowing control for smoking status;
current smoking COPD patients and S were compared to
NS. Cell culture experiments required fresh cells which
had limited availability; we therefore recruited ex-smokersand current smokers, both with and without COPD, for
these experiments. All subjects gave written informed con-
sent. This research was approved by the local research eth-
ics committee.
Tissue sampling and processing
Tissue blocks were labelled with LXRα or LXRβ, as de-
scribed in Additional file 2.
Details of lung tissue RNA extraction are in Additional
file 2.
Alveolar macrophage isolation and culture
Alveolar macrophages were isolated from lungs as previ-
ously described [22]. Macrophages were analysed for LXRα
and LXRβ mRNA expression (described in Additional
file 2).
LXR dependent genes
Macrophages were cultured with GW3965 (1 μM) (Sigma-
Aldrich) or vehicle control (DMSO 0.05%, now referred to
as “vehicle”) for 4, 24, or 48 h. RNA extraction and real
time PCR analysis for expression levels of ABCA1,
ABCG1, toll-like receptor 4 (TLR4), hemeoxygenase 1
(HO-1), cluster of differentiation (CD) 36, and mannose re-
ceptor (MR) is described in Additional file 2.
Inflammatory mediator production
Macrophages were cultured with GW3965 (1 or 10 μM),
dexamethasone (1 μM) (Sigma-Aldrich), or vehicle for
1 h followed by LPS (1 μg/ml, Escherichia Coli B6-026,
Sigma-Aldrich) stimulation and inflammatory mediator
production was analysed at 6 and 24 h (described in
Additional file 2).
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Macrophages were cultured with GW3965 (1 or 10 μM)
or vehicle for 1 h followed by LPS stimulation for 1 h.
Protein was extracted and analysed by Western Blot
(described in Additional file 2).
PBMC culture
Full details are in Additional file 2; PBMCs were isolated
and cultured with GW3965 (1 or 10 μM), dexametha-
sone (1 μM), or vehicle for 1 h followed by stimulation
with anti-CD2/3/28 antibody (24 h) and measurement of
supernatant cytokines.
Epithelial cell culture
Full details are in Additional file 2; BEAS-2B cells, a hu-
man bronchial epithelial cell line, (American Type Culture
Collection, Middlesex, UK) were cultured and labelled
with LXRα or LXRβ antibodies. Cells were also cul-
tured with GW3965 (1 or 10 μM), dexamethasone (1 μM),
or vehicle for 1 h followed by LPS (1 μg/ml) [23] or poly I:
C (10 μg/ml) (Invivogen, San Diego, California) [24] stimu-
lation for 24 h. Supernatants were analysed for CXCL10
by ELISA.
Data analysis
Normally distributed data were compared using a re-













































Figure 1 LXRα and LXRβ mRNA expression in whole lung tissue and l
LXRβ mRNA (B and D) in whole lung tissue (A and B) and lung macrophage
and 10 COPD patients. Data shown are median ± range of relative LXRα/β ex
(p<0.05, p<0.01 respectively).a one-way ANOVA followed by an unpaired t-test. Non-
normally distributed data were compared using a Friedman
test followed by a Wilcoxon matched pairs test or a




LXRα and LXRβ mRNA expression levels were analysed
within the whole lung tissue of 10 NS, 10 S, and 10
COPD patients. LXRα and LXRβ mRNA expression
levels were significantly increased in COPD patients and
S compared to NS (Figure 1). LXRα and LXRβ mRNA
expression levels in whole lung tissue were similar in
COPD patients compared to S (p=0.82 and p=0.16
respectively). In macrophages there was no difference
in the mRNA levels between the 3 groups of patients
(Figure 1).
LXR protein expression
LXR protein expression was analysed within formalin
fixed paraffin embedded lung tissue sections of 10 NS,
10 S, and 10 COPD patients. The number of LXRα im-
munoreactive cells was significantly increased in the small
airways epithelium of COPD patients compared to NS
(p=0.03) and S (p=0.007) (Figures 2 and 3). The number















































ung macrophages. The expression of LXRα mRNA (A and C) and
s (C and D) from 10 non-smoking controls (NS), 10 smoking controls (S)





Figure 2 Representative images of LXRα and LXRβ expression in small airway epithelium and subepithelium. The distribution of LXRα
(A, C, and E) and LXRβ (B, D, and F) in the epithelium (red arrow in A) and subepithelium (red arrow in B) of small airways, present in lung
sections of non-smoking controls (NS) (A-B), smoking controls (S) (C-D) and COPD patients (E-F). LXRα and LXRβ were detected using
3,3’-diaminobenzidine (brown; positive LXRα stain indicated by black arrow) and cell nuclei were counterstained using Meyer’s haematoxylin.
Substitution of LXRα (G) and LXRβ (H) primary antibodies for isotype controls displayed no immunoreactivity.
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NS (p=0.01).
The number of LXRα immunoreactive alveolar epithelial
cells was significantly increased in COPD patients com-
pared to both NS and S (p=0.01 and p<0.0001 respectively)
(Figures 4 and 3). There was no significant difference inthe number of LXRβ immunoreactive alveolar epithelial
cells between patient groups.
There were numerically increased numbers of cells
staining positive for LXRα and LXRβ expression in the
subepithelium of small airways of COPD patients, but
the differences between groups did not reach statistical



























































































































































Figure 3 Quantification of LXR protein in lung tissue sections. The distribution of LXRα (white bars) and LXRβ (grey bars) was quantified in the
epithelium (A) and subepithelium (B) of small airways, the alveolar wall (C), in alveolar macrophages (D), and within lymphocytic aggregates (E). Data
shown are mean ± SEM (A, C, and E) or median ± range (B and D) of 10 non-smoking controls (NS) (apart from E n=8), 10 smoking controls (S) (apart
from E n=6) and 10 COPD patients (apart from E n=9). *, ** and *** = significant difference in protein levels (p<0.05, p<0.01 and p<0.001 respectively).
Higham et al. Respiratory Research 2013, 14:106 Page 5 of 15
http://respiratory-research.com/content/14/1/106significance (Figures 2 and 3). There were no significant
differences between groups in the number of LXRα and
LXRβ immunoreactive alveolar macrophages.
LXR was expressed within lymphocyte aggregations,
which are either organised tertiary lymphoid follicles or
lymphocyte clusters without an organised structure [25].
Lymphocyte aggregations were observed in 8 NS, 6 S,
and 9 COPD patients (out of a possible n=10 per group).
The number of LXRα immunoreactive cells was signifi-
cantly increased within the lymphocytic aggregates in
NS and COPD patients compared to S (p=0.03 for both
groups; Additional file 3). There was no difference be-
tween NS and COPD patients. The number of LXRβ im-
munoreactive cells within lymphocytic aggregates was
similar in the three groups.
Effect of GW3965 on alveolar macrophages
LXR dependent genes
Macrophages from 8 S and 8 COPD patients were treated
with the LXR agonist GW3965 and ABCA1 and ABCG1mRNA expression was quantified. GW3965 significantly
increased the gene expression levels of the LXR dependent
genes ABCA1 and ABCG1; see Additional file 4.
Protein secretion
The effect of GW3965 on LPS stimulated inflammatory
mediator production was investigated in macrophages
from 8 S and 7 COPD patients. LPS significantly increased
cytokine production from COPD and S macrophages, with
the increase in CXCL10 in COPD patients failing to reach
statistical significance (p=0.09) (Additional file 5).
GW3965 (10 μM) significantly inhibited the produc-
tion of CXCL10 and CCL5 from S macrophages by 44%
and 35% respectively (p=0.006 and p=0.02 respectively;
see Figure 5). GW3965 (10 μM) reduced the production
of CXCL10 and CCL5 from COPD macrophages by 38%
and 30% respectively, but these changes did not reach stat-
istical significance (p=0.1 and p=0.2 respectively). GW3965
did not significantly alter the production of GM-CSF,




Figure 4 Representative images of LXRα and LXRβ expression in alveolar epithelium and alveolar macrophages. The distribution of LXRα
(A, C, and E) and LXRβ (B, D, and F) in the alveolar wall (red arrow in B) and in alveolar macrophages (red arrow in D) present in lung sections
of NS (A-B), S (C-D) and COPD patients (E-F). Positive LXRα stain indicated by black arrow.
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release from S by 37% and caused a non-significant in-
crease from COPD macrophages by 45% (p=0.3). Dexa-
methasone significantly inhibited the production of all
cytokines from S and COPD patients apart from CXCL10
(p=0.06 and p=0.1 respectively). The effects of dexametha-
sone were similar in COPD patients and S (p>0.05 for each
cytokine).
The effects of GW3965 on CXCL10, CCL5 and IL-10
were numerically similar in COPD patients and S, but
were not statistically significant in COPD patients; this
may have been due to variability in the limited sample
size available from lung surgical resections. We thereforepooled the data from the two groups to increase the power
of the statistical analysis (see Figure 6); this pooled analysis
showed significant inhibition of CXCL10 and CCL5 as
previously noted, but also significant inhibition of GM-
CSF and IL-6, (19% and 19% inhibition for both cytokines
at 10 μM). The significant increase in IL-10 production
was observed again. Dexamethasone significantly inhibited
the production of all cytokines.
Gene expression
Having demonstrated that GW3965 inhibited LPS-induced
CXCL10 protein secretion from alveolar macrophages, we
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Figure 5 The effect of GW3965 on LPS stimulated inflammatory mediator production in alveolar macrophages from COPD patients
and S compared. Results are presented separately for macrophages from smoking controls (n=8) and COPD patients (n=7) that were treated
with GW3965 (1 μM or 10 μM) (white bars), or dexamethasone (1 μM) (dark grey bars) for 1 h prior to stimulation with LPS (1 μg/ml) for 24 h.
Culture supernatants were analysed for CXCL10 (A), CCL5 (B), IL-10 (C), GM-CSF (D), IL-6 (E), CXCL8 (F), IL-1β (G), and TNFα (H). Data shown are
mean ± SEM. * and ** = significant mediator reduction below vehicle control calculated using absolute values (p<0.05 and p<0.01 respectively).
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patients in order to understand if this effect was also ob-
served at the level of gene transcription. LPS increased
CXCL10 mRNA expression at 6 h but not 24 h (Additional
file 6). The effect of GW3965 (10 μM) on CXCL10 mRNA
production was therefore studied at 6 h; LPS-induced
expression of CXCL10 mRNA was inhibited by 40% from
S and 38% from COPD patients (p=0.08 and p=0.008
respectively) (Figure 7).
The effect of LXR activation on STAT1 phosphorylation
CXCL10 expression is regulated by STAT1 in response
to LPS [26] and LXR activation has previously been
shown to reduce STAT1 phosphorylation in the human
macrophage THP-1 cell line [27]. We therefore studied
the effect of GW3965 on STAT1 phosphorylation in LPS
stimulated macrophages from 3 S and 3 COPD patients.
STAT1 is activated by phosphorylation at two sites; tyro-
sine 701 and serine 727. LPS stimulation predominantly
induces phosphorylation at serine 727 [28].
LPS treatment of S macrophages significantly induced
the phosphorylation of STAT1 (727) (p=0.003). LPS treat-
ment of macrophages from COPD patients induced the
phosphorylation of STAT1 (727), but this did not reach
statistical significance (p=0.07). GW3965 did not signifi-
cantly inhibit the phosphorylation of STAT1 (727) in S
or COPD macrophages even at the highest concentration
(10 μM) (p=0.3 for both groups; Additional file 7).
The effect of LXR activation on macrophage polarisation
We earlier showed that GW3695 upregulated the gene
expression levels of the LXR target genes ABCA1 and
ABCG1. Now, we observed that GW3965 (1 μM and
10 μM) did not change the expression levels of the
known M2 associated genes HO-1, CD36, and MR in S
and COPD macrophages (n=8 for both groups) after cul-
ture for 4, 24 and 48 h (Additional file 8). In contrast to a
previous report [29] we found there was no significant in-
duction of TLR4 gene expression in response to LXR ac-
tivation in both COPD and S macrophages (Additional
file 8).
PBMC culture
As we had found LXRα and LXRβ immunostaining in
lymphoid aggregates of COPD patients and controls
(Additional file 3), we decided to investigate the func-
tional effects of LXR activation on cytokine production
from peripheral blood lymphocytes of 10 NS and 10
COPD patients. The lymphocytes within PBMCs were ac-
tivated with anti-CD2/3/28 antibodies, thus significantly
increasing cytokine production from NS and COPD pa-
tients (Additional file 9). There were no differences in the
basal or stimulated cytokine levels between groups.GW3965 significantly reduced IL-2 and IL-17 release
from NS, with 41% and 25% inhibition respectively at
10 μM (p<0.0001, and p=0.01 respectively; Figure 8). There
was no effect on IL-10 or IL-13 release. GW3965 (10 μM)
significantly inhibited IL-2 production from COPD pa-
tients by 20% but had no effect on IL-17, IL-10 or IL-13
release. The effect of GW3965 (10 μM) on IL-2 was
significantly lower in COPD patients compared to NS
(p=0.001). Dexamethasone significantly reduced IL-2,
IL-10, IL-13, and IL-17 release from NS and COPD pa-
tients; this ranged between 57-94% for NS and 57-93% for
COPD patients, with no differences between groups.
Epithelial cell culture
As we had found LXRα and LXRβ immunostaining in
bronchial epithelial cells of COPD patients and controls,
we investigated the functional effects of LXR activation
on cytokine production from a human bronchial epithe-
lial cell line (BEAS-2B). Firstly, we confirmed that this
cell line expressed LXRα and LXRβ (Additional file 10).
Stimulation of BEAS-2Bs with poly I:C (10 μg/ml), but
not LPS (1 μg/ml), significantly increased the production
of CXCL10 (p=0.01). Poly I:C stimulation was therefore
used to investigate the anti-inflammatory effects of LXR
activation. Pre-treatment of BEAS-2Bs with GW3965
did not significantly inhibit the production of CXCL10
(Additional file 10). In contrast, pre-treatment with dexa-
methasone significantly inhibited CXCL10 production by
89% (p=0.02).
Discussion
We now summarise our findings; LXR gene and protein
expression levels were similar in COPD macrophages
compared to controls. GW3965 upregulated the expression
of the known LXR target genes ABCA1 and ABCG1 in
COPD alveolar macrophages, confirming the pharmaco-
logical activity of this drug on these cells. However, there
was no effect on M2 gene expression. GW3965 had a mod-
est inhibitory effect on the production of some cytokines
including CCL5 and CXCL10, with the clearest effect in
COPD macrophages observed on CXCL10 mRNA levels.
There was also an increase in the production of the anti-
inflammatory cytokine IL-10. However, LXR activation did
not suppress the production of TNFα, IL-1β or CXCL8. It
appears that LXR activation had modest anti-inflammatory
effects on COPD alveolar macrophages; with notable
effects on CXCL10 (suppression) and IL-10 (increased)
production.
GW3965 inhibited CXCL10 and CCL5 secretion and
increased IL-10 production in COPD and S alveolar
macrophages, with the maximum changes being ap-
proximately 40% in both groups. Despite the similar nu-
merical magnitude of effect in both groups, statistical































































































































































Figure 6 The effect of GW3965 on LPS stimulated inflammatory mediator production in alveolar macrophages; pooled analysis. Results
are combined for macrophages from smoking controls (n=8) and COPD patients (n=7) that were treated with GW3965 (1 μM or 10 μM) (white bars),
or dexamethasone (1 μM) (dark grey bars) for 1 h prior to stimulation with LPS (1 μg/ml) for 24 h. Culture supernatants were analysed for CXCL10 (A),
CCL5 (B), IL-10 (C), GM-CSF (D), IL-6 (E), CXCL8 (F), IL-1β (G), and TNFα (H). Data shown are mean ± SEM of combined results. *, ** and *** = significant
mediator reduction below vehicle control calculated using absolute values (p<0.05, p<0.01 and p<0.001 respectively).
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duced CXCL10 expression in COPD macrophages. We
suggest that the overall interpretation of these cytokine
protein and gene expression data is that GW3965 has
similar effects in both COPD and S alveolar macro-
phages, but that the sample size in the COPD protein
experiments was insufficient to demonstrate statistical
significance. Alternatively, the discordance between gene
and protein data maybe due to post-transcriptional
mechanisms which interfere with the efficient translation
of the mRNA product to the mature protein.
We subsequently pooled the COPD and S protein data
with interesting consequences; the effects of GW3965
became apparent at 1 μM as well as 10 μM for CCL5,
highlighting the increased statistical power of this pooled
analysis. Furthermore, the increased sample size allowed
inhibitory effects on GM-CSF and IL-6 to become appar-
ent. Nevertheless, the magnitude of inhibition achieved in
this pooled analysis was 41% or lower, which was generally
less than the corticosteroid dexamethasone. However, the
suppressive effect of GW3965 on CXCL10 was at least
equal to corticosteroid. Furthermore, GW3965 increased
IL-10 production, while corticosteroid reduced the levels
of this anti-inflammatory cytokine.
LXR and the glucocorticoid receptor (GR) are nuclear
hormone receptors that are known to target subsets of
the inflammatory genome [14]. Our findings indicate
that GR activation has much greater efficacy than LXR
activation on many pro-inflammatory cytokines released
by COPD macrophages. However, LXR activation may
still have some useful anti-inflammatory effects that are
driven through CXCL10 inhibition and increased IL-10
production.
The effects of LXR activation are different in our study
and the report of Birrel et al.; for example, we did not























Figure 7 The effect of GW3965 on CXCL10 mRNA expression in LPS stim
(A) (n=8) and COPD patients (B) (n=8) were treated with vehicle (DMSO 0.05%
for 6 h. Data shown are median ± range of fold change. ** = significant diff
ns=non-significant.studies demonstrated IL-6 suppression. The differences
are hard to explain. Both studies obtained macrophages
from surgical specimens. We clinically classified the pa-
tients as COPD or controls, but did not observe a dif-
ference between groups; differences between patients
therefore cannot explain the lack of effect that we have ob-
served. We demonstrated that GW3965 activated LXR;
this was verified by ABCA1 and ABCG1 gene expression
upregulation. We speculate that the effect of LXR on the
production of some macrophage derived cytokines is at
best modest; Birrel et al. showed inhibition that was often
below 50%. Such modest effects may not be reproducible.
CXCL10 levels are increased in the lungs of COPD pa-
tients [30]; this chemokine plays a role in T lymphocyte
chemotaxis through binding to CXCR3. The number of
CD8 cells and the expression of CXCR3 are increased in
the lungs of COPD patients [30], suggesting a prominent
role for CXCL10 – CXCR3 interactions in the control of
lymphocyte chemotaxis in COPD. Furthermore, the
number of lymphoid follicles in the lungs increases with
COPD severity [31]; these are organised structures that
control antigen presentation and adaptive immune func-
tion. CXCL10 is involved in the organisation of these
follicles [32]. LXR agonists may have a potential thera-
peutic role in COPD through inhibition of the produc-
tion of this chemokine.
CXCL10 is an interferon inducible protein whose tran-
scription is regulated by STAT1 in response to inter-
feron gamma (IFN-γ) [33] and LPS [26] exposure. Li
et. al reported that the endogenous LXR agonist, 22-
(R)-hydroxycholesterol, reduces IFN-γ stimulated STAT1
phosphorylation in THP-1 macrophages [27]. In contrast,
we found GW3965 did not reduce STAT1 phosphorylation
in alveolar macrophages. These differences may be due to
ligand specificities, as Li et. al also found that the LXR























ulated alveolar macrophages. Macrophages from smoking controls
) or GW3965 (1 μM or 10 μM) for 1 h prior to LPS (1 μg/ml) stimulation























































































































































Figure 8 The effect of GW3965 on anti- CD2/3/28 stimulated inflammatory mediator production from PBMCs. PBMCs isolated from the
peripheral blood of non-smoking controls (A, C, E, and G) and COPD patients (B, D, F, and H) (n=10 for both groups) were treated with
GW3965 (1 μM or 10 μM) (white bars), or dexamethasone (1 μM) (dark grey bars) for 1 h prior to anti-CD2/3/28 stimulation for 24 h. Culture
supernatants were analysed for IL-2 (A-B), IL-10 (C-D), IL-13 (E-F), and IL-17 (G-H). Data shown are mean ± SEM. *, **, and *** = significant
mediator reduction below vehicle control calculated using absolute values (p<0.05, p<0.01, and p<0.001 respectively).
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were shown to attenuate STAT1 DNA binding [27]. The
same observations have also been demonstrated in rat
brain astrocytes [17]. We hypothesise that this is the mech-
anism by which LXR causes inhibition of LPS stimulated
CXCL10 in alveolar macrophages.
COPD macrophages are skewed towards the alternative
activation phenotype [19]. The phenotypic activity of mac-
rophages is probably under dynamic control of extracel-
lular signals. This regulation involves the cholesterol
transporter ABCA1 in murine macrophages [21]. We have
shown that LXR activation of ABCA1 does not promote
the transcription of M2 genes in COPD macrophages, thus
ruling out a potentially therapeutic role for LXR agonists
in altering macrophage phenotype in COPD.
The gene expression levels of LXRα and LXRβ in
whole lung tissue of COPD patients and S were increased
compared to NS, indicating that chronic cigarette smoke
exposure upregulates LXR gene expression. There was also
an increase in the number of LXR immunoreactive bron-
chial and alveolar epithelial cells in COPD patients, with
evidence for higher expression compared to both S and
NS, suggesting that the development of COPD is associ-
ated with an upregulation of LXR protein expression in
these specific cell types.
The whole lung gene expression levels did not match
the protein expression data for individual cell types, as
the protein data showed more evidence for upregulation
of LXR expression due to COPD itself, rather than
cigarette smoking alone. Whole lung gene expression
takes into account all cell types, which may have variations
in LXR regulation. Furthermore, it is not possible to con-
trol for the proportion of different cell types in whole lung
samples, and the presence of inflammation and emphy-
sema in COPD samples will alter the proportion of cell
types present compared to controls. The gene and protein
expression data from alveolar macrophages were similar,
showing no differences between groups; this demonstrates
good agreement between gene and protein expression
when cell types are matched. Protein expression is ultim-
ately more relevant for physiological function, and we sug-
gest that our data for protein is more relevant, showing
that COPD patients have increased LXR expression in
bronchial and alveolar epithelial cells.
LXR regulates its own expression; LXR activation in-
creases LXR gene expression in human macrophages
[34,35]. LXR activation in the lungs of COPD patients
could be through the endogenous ligands 25- and 27-
hydroxycholesterol, both of which are increased in the
induced sputum of COPD patients [36,37]. The expres-
sion levels of the hydroxylases responsible for the pro-
duction of these oxysterols are also increased in the lung
tissue of COPD patients [36,37]. Abnormal lipid metab-
olism could therefore be the cause of increased LXRexpression in the lungs of COPD patients, with LXR act-
ing in these circumstances to promote cholesterol efflux
[8,20]. LXR transcription is also regulated by PPAR (per-
oxisome proliferator-activated receptor) γ [38,39] and by
cigarette smoke directly [40]. These may also influence
LXR expression and therefore LXR dependent choles-
terol efflux in the lungs of COPD patients.
This is the first study to compare the effects of LXR
activation on lymphocyte derived cytokines from COPD
patients and NS PBMCs. GW3965 inhibited IL-2 and
IL-17 production, with a reduced effect observed in
COPD patients. Walcher et. al also showed that LXR ac-
tivation using T01317 reduced anti-CD3/28 stimulated
IL-2 release from NS PBMCs by a similar magnitude to
our results; approximately 20%. The anti-inflammatory
effects of LXR activation were much lower than dexa-
methasone in the current study, and were also more
cytokine selective as only IL-2 and IL-17 production
were inhibited. It is known that nuclear hormone recep-
tors only target a proportion of the inflammatory gen-
ome [14], and it seems that LXR activation causes a
restricted anti-inflammatory effect compared to cortico-
steroids in lymphocytes. The number of lymphocytes in
the lungs of COPD patients are increased [31], and these
cells release a variety of cytokines [41,42]. The restricted
nature of the anti-inflammatory activity of LXR on se-
lected cytokines in lymphocytes, coupled with the reduced
effect size compared to corticosteroids, makes it unlikely
that the in-vitro anti-inflammatory effects reported here
would translate into clinically meaningful benefits in
COPD patients. Furthermore, the reason for the lower effi-
cacy of GW3965 in COPD patients compared to controls
is unclear, but casts additional doubt on whether LXR acti-
vation would produce meaningful effects on lymphocyte
activation in COPD.
Although GW3965 reduced LPS stimulated CXCL10
production in alveolar macrophages, we did not observe
inhibition of poly I:C stimulated CXCL10 production in
bronchial epithelial cells. These differences in findings
are likely to be due to differences between cell types and/or
the activating stimulus used. Similarly, the effect of cortico-
steroid on CXCL10 release from bronchial epithelial cells
was greater than that observed in alveolar macrophages,
which again may be attributed to cell type and/or stimulus.
Nevertheless, the increased expression of LXR in bronchial
epithelial cells in COPD patients suggests a role for this
protein in the pathophysiology of COPD. This may be elu-
cidated through further studies investigating the effects of
LXR on the transactivation and transrepression of epithe-
lial genes. There is data showing that LXR activation in
human monocytes increases TNFαmRNA levels and intra-
cellular protein accumulation prior to release [43]. LXR ac-
tivation has also been shown to worsen disease progression
in murine models of asthma [44] and arthritis [45].
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pression which may lead to an exaggerated response to
LPS [29]. We did not observe any increase in TLR4 ex-
pression, or any increase in cytokine release from alveo-
lar macrophages caused by LXR activation, suggesting
that LXR activation in this cell type does not cause pro-
inflammatory effects.
We have previously demonstrated that corticosteroids
have a limited inhibitory effect on the production of some
cytokines from COPD alveolar macrophages [22,46,47].
The effect of dexamethasone in the current study is similar
to our previous observations, including the finding of a
modest effect on CXCL10 production [47].
Conclusion
Previous reports have showed that LXR agonists sup-
press the production of some cytokines from macro-
phages [13,18], leading us to evaluate the potential of
LXR activation in COPD macrophages. We observed that
LXR activation caused only modest anti-inflammatory ef-
fects on selected cytokines released from COPD alveolar
macrophages. The most interesting findings were that
CXCL10 production was suppressed and that IL-10 pro-
duction was increased. LXR agonists are being developed
as a potential treatment for cardiovascular disease [11].
Perhaps the most appropriate clinical avenue for the
development of LXR agonists in COPD would be for
those patients with concurrent cardiovascular disease,
as a dual benefit on plaque formation coupled with anti-
inflammatory effects in the lung could be observed.Additional files
Additional file 1: Subject demographics for peripheral blood donors.
Data shown are mean (sd). NS: non-smokers, FEV1: forced expiratory volume
in 1s, FVC: forced vital capacity, ICS: inhaled corticosteroid.
Additional file 2: Materials and methods.
Additional file 3: Representative images of LXRα and LXRβ expression
in lymphocytic aggregates. The distribution of LXRα (A, C, and E) and LXRβ
(B, D, and F) within lymphocytic aggregates present in lung sections of
non-smoking controls (NS) (A-B), smoking controls (S) (C-D), and COPD
patients (E-F).
Additional file 4: The effect of GW3965 on ABCA1 and ABCG1 mRNA
expression in alveolar macrophages. Macrophages from smoking
controls (A and C) (n=8) and COPD patients (B and D) (n=8) were treated
with or without GW3965 (1 μM) for 4, 24 and 48 h. RNA was extracted for
PCR analysis of ABCA1 (A and B) and ABCG1 (C and D) mRNA expression.
Data shown are median ± range of fold increase of mRNA expression above
time matched controls. * and ** = significant difference compared to time
matched controls (p<0.05 and p<0.01 respectively).
Additional file 5: The effect of LPS on cytokine and chemokine
production from alveolar macrophages. Data shown are mean (sd) or
median ± range from 8 S and 7 COPD patients. *, **, and *** = significant
difference from unstimulated control (p<0.05, p<0.01, and p<0.001
respectively). S: smokers.
Additional file 6: The expression of CXCL10 mRNA in LPS
stimulated alveolar macrophages. Macrophages from smokingcontrols (n=8) (A) and COPD patients (n=8) (B) were stimulated with LPS
(1 μg/ml) for 6 or 24 h prior to RNA extraction and PCR analysis for
CXCL10. Data shown are median ± range. * = significant difference
compared to time matched control (p<0.05).
Additional file 7: The effect of GW3965 on the phosphorylation of
STAT1 (727). Macrophages from smoking controls (n=3) (A) and COPD
patients (n=3) (B) were treated with vehicle control (DMSO 0.05%) or
GW3965 (1 μM or 10 μM) for 1 h prior to stimulation with LPS (1 μg/ml)
for 1 h. Macrophages were then lysed and samples were analysed for
phosphorylated STAT1 (727) by western blot. All blots were analysed by
densitometry and any changes were relative to the loading control β-actin.
Data shown are mean ± SEM with representative blots below. * = significant
difference compared to unstimulated control (p<0.05).
Additional file 8: The effect of GW3965 on macrophage polarisation.
Alveolar macrophages from smoking controls (A, C, E, and G) (n=8 apart
from at 10 μM n=5) and COPD patients (B, D, F, and H) (n=9 apart from at
10 μM n=3) were treated with or without GW3965 (1 μM and 10 μM) for
4, 24 and 48 h. RNA was extracted for PCR analysis of HO-1 (A and B),
CD36 (C and D), MR (E and F) and TLR4 (G and H) mRNA expression. Data
shown are mean ± SEM of fold increase of mRNA expression above time
matched controls.
Additional file 9: The effect of anti-CD2/3/28 stimulation on cytokine
production from PBMCs. Data shown are mean (sd) or median ± range
from 10 NS and 10 COPD patients. * = significant induction of mediator
compared to unstimulated control (p<0.001). NS: non-smokers.
Additional file 10: The effect of GW3965 on the production of
CXCL10 from poly I:C stimulated BEAS-2Bs. Immunocytochemical
staining confirmed the presence of LXRα (A) and LXRβ (B) in BEAS-2Bs.
Omission of the primary antibodies displayed no immunoreactivity for
LXRα (C) and LXRβ (D). (E) BEAS-2Bs (n=3) were pre-treated with vehicle
(DMSO 0.05%) (white bars), GW3965 (1 μM or 10 μM) (light grey bars), or
dexamethasone (1 μM) (dark grey bars) for 1 h prior to stimulation with
poly I:C (10 μg/ml) for 24 h. Culture supernatants were analysed for
CXCL10. Data shown are mean ± SEM where * = significant reduction of
CXCL10 below vehicle control (p<0.05).Competing interests
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